Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care is organized by Physicians' Education Resource, LLC (PER).
Release Date: January 31, 2023
Expiration Date: January 31, 2024
Description:
The application of liquid biopsy across different malignancies is rapidly evolving as technologies continue to advance and new data support their expanding use in various clinical contexts. In general, liquid biopsy refers to sampling from the peripheral blood and other compartments in the body, isolating circulating tumor cells, cell-free DNA, and other materials to perform noninvasive genetic testing that may inform treatment decision-making. Understanding the applications of these technologies, as well as the data informing their use, is critical for practicing oncologists.
This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 6th Annual Precision Medicine Through Plasma™ held in November 2022. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of integrating liquid biopsies into the management of patients with gastrointestinal, breast, and lung cancers by putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Assess the relative advantages of currently available liquid-based and tissue-based testing approaches
• Review the capabilities of currently available liquid biopsy technologies
• Appraise the utility of liquid biopsies for different cancers, including non–small cell lung cancer, breast cancer, and gastrointestinal cancers
• Apply clinical evidence on specific testing modalities that may help to individualize treatment protocols for patients with cancer.